The Library
Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer
Tools
Tools
Tools
UNSPECIFIED (2002) Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer. In: Satellite Symposium on Gemcitabine and Targeted Therapies in Thoracic Cancer held in Conjunction with the European Conference on Perspectives in Lung Cancer, LONDON, ENGLAND, DEC, 2001. Published in: LUNG CANCER, 38 (Suppl. 2). S21-S28. ISSN 0169-5002.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Abstract
The introduction of any new chemotherapy agent for non-small cell lung cancer (NSCLC) ought to be considered carefully in light of both costs and measurable benefits. Decision making is straightforward if a new treatment is relatively cheaper and more effective (i.e. introduce new therapy) or more expensive and less effective (i.e. reject new treatment) than standard therapies. However, if a treatment is more expensive and also more effective, or less expensive but also less effective, decision making becomes more complicated. An economic evaluation of the cost-effectiveness of gemcitabine in advanced NSCLC was performed as a case study. A comprehensive literature search for published economic evaluations of gemcitabine was carried out. Economic studies examining treatment for advanced NSCLC were limited to cost-minimization analyses and cost-effectiveness analyses. The analyses included primary economic studies, e.g. trials that included an integral economic evaluation, and secondary research, e.g. analyses based on published trial data and modeling. Overall, gemcitabine regimens proved cost-effective against standard therapies in this analysis. Prospective economic and quality-of-life analyses should be incorporated into study designs to help identify treatments that will maximize societal health benefits. (C) 2002 Published by Elsevier Science Ireland Ltd.
| Item Type: | Conference Item (UNSPECIFIED) | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RC Internal medicine |
||||
| Journal or Publication Title: | LUNG CANCER | ||||
| Publisher: | ELSEVIER SCI IRELAND LTD | ||||
| ISSN: | 0169-5002 | ||||
| Official Date: | November 2002 | ||||
| Dates: |
|
||||
| Volume: | 38 | ||||
| Number: | Suppl. 2 | ||||
| Number of Pages: | 8 | ||||
| Page Range: | S21-S28 | ||||
| Publication Status: | Published | ||||
| Title of Event: | Satellite Symposium on Gemcitabine and Targeted Therapies in Thoracic Cancer held in Conjunction with the European Conference on Perspectives in Lung Cancer | ||||
| Location of Event: | LONDON, ENGLAND | ||||
| Date(s) of Event: | DEC, 2001 |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
